Inozyme Pharma Stock Cash And Equivalents
| INZYDelisted Stock | USD 4.00 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inozyme Pharma's long-term financial health and intrinsic value.
Inozyme |
Inozyme Pharma Company Cash And Equivalents Analysis
Inozyme Pharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Inozyme Pharma Cash And Equivalents | 151.48 M |
Most of Inozyme Pharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Inozyme Pharma has 151.48 M in Cash And Equivalents. This is 81.55% lower than that of the Biotechnology sector and 66.12% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 94.39% higher than that of the company.
Inozyme Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in cash and equivalents category among its peers.
Inozyme Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.48 | |||
| Current Valuation | 220.43 M | |||
| Shares Outstanding | 64.56 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 94.29 % | |||
| Number Of Shares Shorted | 3.38 M | |||
| Price To Book | 8.12 X | |||
| EBITDA | (104.03 M) | |||
| Net Income | (102.02 M) | |||
| Cash And Equivalents | 151.48 M | |||
| Cash Per Share | 3.77 X | |||
| Total Debt | 46.87 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 14.54 X | |||
| Book Value Per Share | 0.49 X | |||
| Cash Flow From Operations | (91.91 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.68) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.29 | |||
| Market Capitalization | 258.25 M | |||
| Total Asset | 123.18 M | |||
| Retained Earnings | (387.95 M) | |||
| Working Capital | 86.78 M | |||
| Net Asset | 123.18 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Inozyme Stock
If you are still planning to invest in Inozyme Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inozyme Pharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |